Table 3. Cox regression analysis for PFS and OS for advanced-stage ENKTL patients treated with PEMD (N=32).

Characteristic	PFS				OS
	Univariate analysis		Multivariate analysis		Univariate analysis		Multivariate analysis
	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P	HR (95% CI)	P
Male	2.30 (0.52–10.01)	0.27	—	—	1.93 (0.43–8.63)	0.39	—	—
Nasal subtype	1.45 (0.50–4.20)	0.49	—	—	1.67 (0.56–4.99)	0.36	—	—
Age >60 years	2.15 (0.77–5.96)	0.14	—	—	2.67 (0.92–7.80)	0.07	—	—
LDH >ULN	3.40 (1.17–9.88)	0.02	2.01 (0.60–6.74)	0.26	3.66 (1.13–11.75)	0.03	1.80 (0.51–6.36)	0.36
ECOG score ⩾2	0.59 (0.17–2.07)	0.41	—	—	0.81 (0.22–2.92)	0.74	—	—
Distant lymph-node involvement	1.11 (0.37–3.32)	0.85	—	—	0.81 (0.27–2.49)	0.72	—	—
IPI score ⩾3	3.67 (1.17–11.47)	0.03	1.77 (0.48–6.54)	0.39	7.84 (1.73–35.49)	<0.01	5.02 (0.95–26.5)	0.06
PINK ⩾2	4.03 (1.46–11.08)	0.02	5.60 (1.46–21.54)	0.01	3.46 (1.21–9.88)	0.04	4.56 (1.12–18.50)	0.03
B-symptoms	1.74 (0.49–6.13)	0.39	—	—	2.33 (0.52–10.43)	0.27	—	—
EBV-DNA-positivity	3.32 (1.11–9.93)	0.02	5.19 (1.73–15.52)	<0.01	3.88 (1.26–11.95)	0.01	6.97 (2.05–23.62)	<0.01
Extranodal site >1	1.58 (0.59–4.25)	0.37	—	—	2.28 (0.76–6.83)	0.14	—	—

Abbreviations: CI, confidence interval; EBV, Epstein-Barr virus; ECOG, Eastern Cooperative Oncology Group; ENKTL, extra-nodal natural-killer (NK)/T-cell lymphoma; HR, hazard ratio; IPI, International Prognostic Index; LDH, lactate dehydrogenase; OS, overall survival; PEMD, pegaspargase, etoposide, methotrexate and dexamethasone; PFS, progression-free survival; PINK, prognostic index of natural killer lymphoma; ULN, upper limit of normal. Bold signifies P<0.05.